IMMP News and Press, Immutep Limited From 09/01/21

Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Last 2 nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recruitment of Stage 2 of Part B Total of 154 patients out of up to 183 patients (84%) now participating in...

Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“ Immutep ” or the “ Company ”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti...

Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody mole...

Immutep (NASDAQ:IMMP) announces that the first patient has been dosed in the investigator-initiated trial for the triple combination including eftilagimod alpha for the treatment of metastatic non-small cell lung carcinoma. The patient with metastatic non-small cell lung c...

Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“ Immutep ” or the “ Company ”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re in the final stretch of the week with just one more day of trading to go. So let’s start it off right with a look at the biggest pre-market stock movers for Friday! Source: Er...

Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States to commence TACTI-003 Patient recruitment into the trial is expected to begin w...

Immutep (IMMP) has received commitments for a A$60M two-tranche private placement of new ordinary shares.The Placement will involve the issue of New Shares at an issue price of A$0.52/share. The proceeds will be used to fund the expansion of clinical programs and to commence the process chara...

Immutep (IMMP) has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha (“efti” or “IMP321”) in conjunction with an existing approved standard of care therapy consisting of ...

Immutep (IMMP) -14% after expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapyAshford Hospitality Trust (AHT) -10% after inks stock purchase agreement with Seven Knots.BIT Mining (BTCM) -9%.Riot Blockchain (RIOT) -8%....